Shah-naz H Khan, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1020 Charter Dr Ste C, Flint, MI 48532 Phone: 810-212-4100 Fax: 810-250-4514 |
Atya Alfllouse, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 4800 S Saginaw St, Flint, MI 48507 Phone: 810-275-9333 |
Dr. Hugo Lopez Negrete, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: G3239 Beecher Rd, Flint, MI 48532 Phone: 810-733-7560 Fax: 810-733-2880 |
Dr. Cameron Michael Mcdougall, M.D., FRCS(C) Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4800 S Saginaw St # 4800, Flint, MI 48507 Phone: 248-525-1788 |
Dali Yin, MD, PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4800 S Saginaw St Ste 1800, Flint, MI 48507 Phone: 810-732-8336 |
Sudesh J Ebenezer, MD, ED.M., FRCSC Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4800 S Saginaw St, Suite 1800, Flint, MI 48507 Phone: 810-732-8336 Fax: 810-963-1674 |
Idara John Edem, MD, MSC, FRCPC Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4800 S Saginaw St Ste 1800, Flint, MI 48507 Phone: 810-732-8336 |
Dr. Vivekanand Palavali, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3380 Beecher Road, Ste A, Flint, MI 48532 Phone: 810-820-6311 |
Sirajeddin Suleiman Belkhair, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 4800 S Saginaw St, Suite 1800, Flint, MI 48507 Phone: 810-732-8336 Fax: 810-963-1674 |
News Archive
Following a negative complete colonoscopy, those who had their colonoscopies at a hospital and had their procedures performed by a non-gastroenterologist may be at a significantly increased risk of developing subsequent colorectal cancer (CRC), according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
Doctors have reported that partial or total loss of the sense of smell is often an early symptom of infection with SARS-CoV-2, the virus that causes COVID-19.
The Hill on Tuesday examined how Democratic presidential nominee Sen. Barack Obama (Ill.) and Republican presidential nominee Sen. John McCain (Ariz.) are perceived by the drug and biotech industries.
› Verified 3 days ago